Under the tide of reviews, there has been good news from many pharmaceutical companies in the past week

In recent years, under the background of the normalization of collective procurement, domestic pharmaceutical companies are actively promoting the consistency evaluation of generic drugs to obtain qualifications
to participate in collective procurement.
Affected by this, there is good
news about drug over-evaluation.
It is understood that in the past week, many companies have said that their products have been evaluated
.
Peking University Pharmaceutical Loratadine Tablets Evaluated On October 15, Peking University Pharmaceutical issued an announcement that Loratadine tablets received the "Drug Supplement Application Approval Notice" approved and issued by the State Food and Drug Administration, and the product passed the consistency evaluation
of the quality and efficacy of generic drugs.
Loratadine tablets are used to relieve symptoms associated with allergic rhinitis, such as sneezing, runny nose, nasal itching, nasal congestion, and itching and burning sensation
in the eyes.
Oral medication provides rapid relief of nasal and eye signs and symptoms, and is also suitable for relieving the symptoms and signs
of chronic urticaria, pruritic skin diseases and other allergic skin diseases.
Hengrui Pharmaceutical levobupivacaine hydrochloride injection was evaluated On October 14, Hengrui Pharmaceutical issued an announcement that levobupivacaine hydrochloride injection received the "Drug Supplement Application Approval Notice" issued by the State Food and Drug Administration, and the drug passed the consistency evaluation of generic drugs and was used for the treatment of surgical epidural block anesthesia
.
Levobupivacaine, an isomer of the local anesthetic bupivacaine, is an amide-long-acting local anesthetic and analgesic developed by Celltech Group (now UCB Celltech
).
According to public data, in 2021, the global sales of levobupivacaine-related dosage forms were about $39.
5 million
.
Up to now, Hengrui Pharmaceutical has invested about 4.
19 million yuan
in R&D expenses for the consistency evaluation of generic drugs of levobupivacaine hydrochloride injection.
On October 14, Weixin Rehabilitation Formula Amino Acid Injection was evaluated On October 14, Weixinkang issued an announcement announcing that the compound amino acid injection (20AA) of Inner Mongolia Baiyi Pharmaceutical, a wholly-owned subsidiary, received the "Drug Registration Certificate" approved and issued by the State Food and Drug Administration, and the "Drug Registration Certificate" was deemed to have passed the consistency evaluation
.
Compound amino acid injection (20AA) is a compound preparation composed of a variety of amino acids, which is an intravenous parenteral nutrition infusion, suitable for patients with severe hepatic insufficiency and about to develop or have developed hepatic encephalopathy, providing amino acids
for their parenteral nutrition.
At present, there are many approved manufacturers of compound amino acid injection (20AA) in China, including Chenxin Pharmaceutical Co.
, Ltd.
, Liaoning Haisco Pharmaceutical Co.
, Ltd.
, Jilin Sichang Pharmaceutical Co.
, Ltd.
, and Hubei Bantian Pharmaceutical Co.
, Ltd.

On October 14, the State Food and Drug Administration issued a new batch of drug approval documents to be received, showing that the caspofungin acetate for injection of Sino-American East China Pharmaceutical passed the consistency evaluation
.
It is understood that caspofungin is a semi-synthetic lipopeptide (echinococcin) compound, mainly used for the empiric treatment of neutropenia, fever in patients with suspected fungal infections; candidemia and the following candidal infections: intra-abdominal abscess, peritonitis and pleural cavity infection; Esophageal candidiasis; Invasive aspergillosis
that does not respond to or is not tolerated to other treatments.
Sino-US Huadong Pharmaceutical is the third "over-rated" enterprise
of the drug.
At present, many domestic enterprises are also promoting the consistency evaluation of this variety, such as Sihuan Pharmaceutical
.
Disclaimer: Under no circumstances does the information or opinions expressed in this article constitute investment advice
to anyone.